ACBD3 modulates KDEL receptor interaction with PKA for its trafficking via tubulovesicular carrier.
ACBD3
Arf1-GTP
ArfGAPs
Golgi
KDEL receptor
Protein Kinase A
Journal
BMC biology
ISSN: 1741-7007
Titre abrégé: BMC Biol
Pays: England
ID NLM: 101190720
Informations de publication
Date de publication:
07 09 2021
07 09 2021
Historique:
received:
15
02
2021
accepted:
30
08
2021
entrez:
8
9
2021
pubmed:
9
9
2021
medline:
22
12
2021
Statut:
epublish
Résumé
KDEL receptor helps establish cellular equilibrium in the early secretory pathway by recycling leaked ER-chaperones to the ER during secretion of newly synthesized proteins. Studies have also shown that KDEL receptor may function as a signaling protein that orchestrates membrane flux through the secretory pathway. We have recently shown that KDEL receptor is also a cell surface receptor, which undergoes highly complex itinerary between trans-Golgi network and the plasma membranes via clathrin-mediated transport carriers. Ironically, however, it is still largely unknown how KDEL receptor is distributed to the Golgi at steady state, since its initial discovery in late 1980s. We used a proximity-based in vivo tagging strategy to further dissect mechanisms of KDEL receptor trafficking. Our new results reveal that ACBD3 may be a key protein that regulates KDEL receptor trafficking via modulation of Arf1-dependent tubule formation. We demonstrate that ACBD3 directly interact with KDEL receptor and form a functionally distinct protein complex in ArfGAPs-independent manner. Depletion of ACBD3 results in re-localization of KDEL receptor to the ER by inducing accelerated retrograde trafficking of KDEL receptor. Importantly, this is caused by specifically altering KDEL receptor interaction with Protein Kinase A and Arf1/ArfGAP1, eventually leading to increased Arf1-GTP-dependent tubular carrier formation at the Golgi. These results suggest that ACBD3 may function as a negative regulator of PKA activity on KDEL receptor, thereby restricting its retrograde trafficking in the absence of KDEL ligand binding. Since ACBD3 was originally identified as PAP7, a PBR/PKA-interacting protein at the Golgi/mitochondria, we propose that Golgi-localization of KDEL receptor is likely to be controlled by its interaction with ACBD3/PKA complex at steady state, providing a novel insight for establishment of cellular homeostasis in the early secretory pathway.
Sections du résumé
BACKGROUND
KDEL receptor helps establish cellular equilibrium in the early secretory pathway by recycling leaked ER-chaperones to the ER during secretion of newly synthesized proteins. Studies have also shown that KDEL receptor may function as a signaling protein that orchestrates membrane flux through the secretory pathway. We have recently shown that KDEL receptor is also a cell surface receptor, which undergoes highly complex itinerary between trans-Golgi network and the plasma membranes via clathrin-mediated transport carriers. Ironically, however, it is still largely unknown how KDEL receptor is distributed to the Golgi at steady state, since its initial discovery in late 1980s.
RESULTS
We used a proximity-based in vivo tagging strategy to further dissect mechanisms of KDEL receptor trafficking. Our new results reveal that ACBD3 may be a key protein that regulates KDEL receptor trafficking via modulation of Arf1-dependent tubule formation. We demonstrate that ACBD3 directly interact with KDEL receptor and form a functionally distinct protein complex in ArfGAPs-independent manner. Depletion of ACBD3 results in re-localization of KDEL receptor to the ER by inducing accelerated retrograde trafficking of KDEL receptor. Importantly, this is caused by specifically altering KDEL receptor interaction with Protein Kinase A and Arf1/ArfGAP1, eventually leading to increased Arf1-GTP-dependent tubular carrier formation at the Golgi.
CONCLUSIONS
These results suggest that ACBD3 may function as a negative regulator of PKA activity on KDEL receptor, thereby restricting its retrograde trafficking in the absence of KDEL ligand binding. Since ACBD3 was originally identified as PAP7, a PBR/PKA-interacting protein at the Golgi/mitochondria, we propose that Golgi-localization of KDEL receptor is likely to be controlled by its interaction with ACBD3/PKA complex at steady state, providing a novel insight for establishment of cellular homeostasis in the early secretory pathway.
Identifiants
pubmed: 34493279
doi: 10.1186/s12915-021-01137-7
pii: 10.1186/s12915-021-01137-7
pmc: PMC8424950
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
KDEL receptor
0
Receptors, Peptide
0
Cyclic AMP-Dependent Protein Kinases
EC 2.7.11.11
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
194Informations de copyright
© 2021. The Author(s).
Références
Cell Rep. 2013 Sep 12;4(5):890-7
pubmed: 24012756
EMBO J. 1988 Apr;7(4):913-8
pubmed: 3402439
Cell. 1987 Mar 13;48(5):899-907
pubmed: 3545499
mBio. 2013 Apr 09;4(2):e00098-13
pubmed: 23572552
Methods Enzymol. 2005;404:316-32
pubmed: 16413279
EMBO J. 2017 Nov 2;36(21):3156-3174
pubmed: 28978670
EMBO J. 2012 Feb 1;31(3):754-66
pubmed: 22124328
Mol Biol Cell. 2003 Oct;14(10):4114-25
pubmed: 14517323
Dev Cell. 2019 Sep 9;50(5):573-585.e5
pubmed: 31231041
Traffic. 2009 Mar;10(3):307-15
pubmed: 19055691
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11731-6
pubmed: 18689681
Nat Cell Biol. 2008 Aug;10(8):912-22
pubmed: 18641641
EMBO J. 2001 Jun 15;20(12):3082-91
pubmed: 11406585
J Lipid Res. 2019 Feb;60(2):269-275
pubmed: 30266835
EMBO J. 2012 Jun 29;31(13):2869-81
pubmed: 22580821
J Biol Chem. 2008 Oct 10;283(41):27717-27723
pubmed: 18693248
Nat Methods. 2007 Mar;4(3):207-14
pubmed: 17327847
EMBO J. 1997 Dec 15;16(24):7305-16
pubmed: 9405360
Dev Cell. 2001 Jul;1(1):139-53
pubmed: 11703931
Nature. 1990 Nov 8;348(6297):162-3
pubmed: 2172835
Cell Struct Funct. 2011;36(1):1-12
pubmed: 21150128
J Cell Biol. 1993 Jun;121(5):997-1010
pubmed: 8099077
Exp Cell Res. 2015 Oct 1;337(2):136-45
pubmed: 26183104
Mol Biol Cell. 2017 Jun 15;28(12):1676-1687
pubmed: 28428254
J Cell Biol. 2008 Nov 17;183(4):725-35
pubmed: 19015319
Annu Rev Biochem. 2007;76:629-45
pubmed: 17263661
Cell. 2017 Aug 24;170(5):939-955.e24
pubmed: 28803726
EMBO J. 2001 Dec 3;20(23):6751-60
pubmed: 11726511
mBio. 2016 Jul 12;7(4):
pubmed: 27406559
J Cell Biol. 1994 Dec;127(6 Pt 1):1557-74
pubmed: 7798312
Cell. 1990 Jun 29;61(7):1349-57
pubmed: 2194670
J Immunol. 2007 Jan 15;178(2):1144-50
pubmed: 17202378
Mol Biol Cell. 1997 Jun;8(6):1073-87
pubmed: 9201717
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Virol. 2014 Jun;88(12):6586-98
pubmed: 24672044
Trends Cell Biol. 2016 Nov;26(11):804-817
pubmed: 27667171
Science. 1988 Mar 4;239(4844):1134-7
pubmed: 2964083
EMBO J. 1989 Mar;8(3):681-6
pubmed: 2542023
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Sci Rep. 2015 Jan 27;5:8060
pubmed: 25622827
Sci Rep. 2016 Mar 24;6:23641
pubmed: 27009356
Int J Mol Sci. 2019 Apr 24;20(8):
pubmed: 31022988
Dev Cell. 2015 Apr 20;33(2):189-203
pubmed: 25865347
Science. 2019 Mar 8;363(6431):1103-1107
pubmed: 30846601
Dev Cell. 2014 Aug 11;30(3):280-94
pubmed: 25117681
FEBS Lett. 2009 Dec 3;583(23):3863-71
pubmed: 19854180
Curr Biol. 2013 Oct 7;23(19):1945-51
pubmed: 24076238
Mol Biol Cell. 2004 Nov;15(11):4798-806
pubmed: 15331763
Cell Mol Life Sci. 2021 Feb;78(3):1085-1100
pubmed: 32562023
J Biol Chem. 1999 Jul 16;274(29):20545-9
pubmed: 10400684
J Biol Chem. 2010 Nov 19;285(47):36709-20
pubmed: 20858901
Prog Lipid Res. 2010 Jul;49(3):218-34
pubmed: 20043945
J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):275-83
pubmed: 12943713
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1849-54
pubmed: 24449908
J Cell Biol. 2012 Mar 19;196(6):801-10
pubmed: 22412018
Nat Cell Biol. 1999 Sep;1(5):280-7
pubmed: 10559940
Gene. 2003 Apr 10;308:1-10
pubmed: 12711385